Updates on Keytruda and future potential therapies advancements in Immuno-Oncology
SMi Group reports on preparations for SMi's inaugural Immuno-Oncology Conference, which is scheduled to take place 26 - 27 September in London.
The official programme of Immuno-Oncology Conference is shaping up to be a great platform for discussions between industry leaders. It will inform and update participants on current key areas for development, on future potential therapies advancements and provide revisions of regulations.
One of the highlights in the IO field is KEYTRUDA therapy - a type of immunotherapy that works by blocking the PD-1 pathway and to help prevent cancer cells from hiding. It recently hit the news claiming significant improvement in overall survival rate in newly-diagnosed patients with advanced non-small cell lung cancer. Data came from Merck & Co’s closely-watched study and results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it's found.*
Immuno-Oncology Conference organisers are excited to have Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology of Merck Sharp & Dohme Limited bringing his expertise to the event with his presentation on Keytruda: anticancer therapy across a wide range of malignancies. Kandeepan will provide participants updates on:
- Recent advances in providing durable disease control
- Innovative combination strategies to improve upon monotherapy activity and overcome resistance
- Importance of patient selection in cancer immunotherapy
Also, in the programme pre-conference workshops (25 September):
- Could the Microbiome boost Cancer Immuno-Therapy? - hosted by representatives of ImmuneBiotech and Lund University
- Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by representatives of LucidQuest Ventures
View detailed agenda, find out who is speaking and book to attend at http://www.immuno-oncology-conference.com/pharmaphorum
CONTACT:
+44 (0)20 7827 6000
Twitter - @SMIpharm & #immunooncologysmi
LinkedIn - SMi Pharma
Opt-in - SMi Group value your interest in their events and would like to stay in touch - opt-in via https://www.smi-online.co.uk/opt-in to receive SMi’s updates
*cbsnews.com/news/immunotherapy-keytruda-lung-cancer-study/
